{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:53:09Z","timestamp":1781632389110,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Two Phase 3 clinical trials were conducted to investigate the efficacy and safety of iptacopan, a novel treatment for paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired hemolytic disorder whose most prevalent symptom is fatigue. The FACIT-Fatigue questionnaire version 4 was administered to participants to document change in patient-reported fatigue after receiving treatment with iptacopan. The aim of this study is to further evaluate the psychometric properties of the FACIT-Fatigue as a measure of fatigue among adults with PNH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>Post-hoc analyses were conducted using data from the two clinical trials at Baseline and Days 42, 126, 140, and 168. After description of its item properties (item distribution and item scores over time), the scores produced by the FACIT-Fatigue were evaluated to examine reliability (internal consistency and stability), validity (construct validity, known-groups, and responsiveness to change) and dimensionality. Meaningful within-patient change estimates were also developed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across timepoints, participants endorsed the full range of the FACIT-Fatigue\u2019s response options, and there was monotonicity of responses showing decreasing fatigue severity over time. Dimensionality analyses supported the use of the FACIT-Fatigue total score for measurement of fatigue. The total score demonstrated very high internal consistency reliability (Cronbach\u2019s \u03b1\u2009\u2265\u20090.90) and good to excellent stability (test-retest intra-class correlation \u2265 0.89), correlated with other assessment scores as expected, and was able to distinguish between clinically distinct known groups. Anchor-based analysis suggested meaningful within-patient change for the FACIT-Fatigue total score (possible score range\u2009=\u20090\u201352) to be in the range of 7.5\u20139.5 points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The psychometric results reported here provide evidence suggesting that the scores produced by the FACIT-Fatigue are reliable and valid, and thus may be considered fit for purpose in measuring fatigue among adults with PNH. While unidimensional confirmatory factor analysis did not entirely reflecting a unidimensional model, use of a bifactor model did provide evidence of essential unidimensionality, supporting the conclusion that FACIT-Fatigue total score may be appropriate to use in evaluating treatment efficacy in this target patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-026-00996-4","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:04:39Z","timestamp":1769256279000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psychometric performance of the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue questionnaire among adults with paroxysmal nocturnal hemoglobinuria"],"prefix":"10.1186","volume":"10","author":[{"given":"David","family":"Cella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Vallow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Bermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Ngerano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Linton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Arenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samopriyo","family":"Maitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glorian","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Galipeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1322-1832","authenticated-orcid":false,"given":"Gavin","family":"Dickie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"996_CR1","unstructured":"U.S. Department of Health and Human Services (2009) Food and Drug Administration. Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research; Center for Devices and Radiological Health. Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims. Office of Communications, Division of Drug Information"},{"key":"996_CR2","doi-asserted-by":"publisher","unstructured":"Patrick DL, Burke LB, Gwaltney CJ et al. (2011) Content validity - establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) Instruments for medical product evaluation: ISPOR PRO good Research Practices Task Force Report: part 1-eliciting concepts for a New PRO instrument. Value in Health 14(8):967\u2013977. https:\/\/doi.org\/10.1016\/j.jval.2011.06.014","DOI":"10.1016\/j.jval.2011.06.014"},{"issue":"1","key":"996_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/MLR.0000000000000273","volume":"53","author":"EM Perfetto","year":"2015","unstructured":"Perfetto EM, Burke L, Oehrlein EM, Epstein RS (2015) Patient-focused drug development: a new direction for collaboration. Med Care 53(1):9\u201317. https:\/\/doi.org\/10.1097\/MLR.0000000000000273","journal-title":"Med Care"},{"key":"996_CR4","unstructured":"US Department of Health and Human Services (2020) Food and Drug Administration, center for Drug evaluation and Research, center for Biologics evaluation and Research. Patient-Focused Drug Devel: Collecting Compr And Representative Input - Guid For Ind, Food And Drug Adm Staff, And Other Stakeholders. Office of Commun, Div of Drug Inf"},{"key":"996_CR5","unstructured":"US Department of Health and Human Services (2022) Food and Drug Administration, center for Drug evaluation and Research, center for Biologics evaluation and Research. Guid For Ind, Food And Drug Adm Staff, And Other Stakeholders: Patient-Focused Drug Devel: Methods To Identify What Is Important To Patients. Office of Commun, Div of Drug Inf. 02"},{"issue":"11","key":"996_CR6","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.imbio.2012.07.014","volume":"217","author":"AM Risitano","year":"2012","unstructured":"Risitano AM (2012) Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders. Immunobiology 217(11):1080\u20131087. Novhttps:\/\/doi.org\/10.1016\/j.imbio.2012.07.014","journal-title":"Immunobiology"},{"issue":"100","key":"996_CR7","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.exphem.2021.12.272","volume":"\/08\/01\/2021","author":"D Cella","year":"2021","unstructured":"Cella D, Sarda S, Hsieh R et al. (2021) 3054 -Clinically meaningful and long-term Improvements in Fatigue with the C3 inhibitor Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: post-hoc analyses from the PEGASUS study week 48. Exp Hematol \/08\/01\/2021(100):S68. https:\/\/doi.org\/10.1016\/j.exphem.2021.12.272","journal-title":"Exp Hematol"},{"issue":"5","key":"996_CR8","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1007\/s12325-022-02111-7","volume":"39","author":"S Krishnan","year":"2022","unstructured":"Krishnan S, Sarda S, Kunzweiler C et al. (2022 May) Literature review of Fatigue Scales and Association with Clinically meaningful Improvements in outcomes among patients with and without paroxysmal nocturnal hemoglobinuria. Adv Ther 39(5):1959\u20131975. https:\/\/doi.org\/10.1007\/s12325-022-02111-7","journal-title":"Adv Ther"},{"issue":"3","key":"996_CR9","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1445-5994.2012.02924.x","volume":"43","author":"I Weitz","year":"2013","unstructured":"Weitz I, Meyers G, Lamy T et al. (2013 Mar) Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria. Intern Med J 43(3):298\u2013307. https:\/\/doi.org\/10.1111\/j.1445-5994.2012.02924.x","journal-title":"Intern Med J"},{"issue":"6","key":"996_CR10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","volume":"133","author":"AG Kulasekararaj","year":"2019","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST et al. (2019 Feb 7) Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood 133(6):540\u2013549. https:\/\/doi.org\/10.1182\/blood-2018-09-876805","journal-title":"Blood"},{"key":"996_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2020-142453","volume":"136","author":"H Schrezenmeier","year":"2020","unstructured":"Schrezenmeier H, Lee J, Hill A et al. (2020) Efficacy and safety of concomitant use of Ravulizumab and IST in patients with paroxysmal nocturnal hemoglobinuria up to 52 weeks. Blood 136:37\u201338","journal-title":"Blood"},{"issue":"11","key":"996_CR12","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","volume":"384","author":"P Hillmen","year":"2021","unstructured":"Hillmen P, Szer J, Weitz I et al. (2021) Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 384(11):1028\u20131037. https:\/\/doi.org\/10.1056\/NEJMoa2029073","journal-title":"N Engl J Med"},{"key":"996_CR13","unstructured":"US Food and Drug Administration. Clinical Outcome Assessment Compendium. Accessed 08\/31\/2022, https:\/\/www.fda.gov\/drugs\/development-resources\/clinical-outcome-assessment-compendium"},{"issue":"11","key":"996_CR14","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa2308695","volume":"390","author":"R Peffault de Latour","year":"2024","unstructured":"Peffault de Latour R, R\u00f6th, Kulasekararaj AG et al. (2024) Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria. N Engl J Med 390(11):994\u20131008","journal-title":"N Engl J Med"},{"issue":"2","key":"996_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1037\/met0000045","volume":"21","author":"A Rodriguez","year":"2016","unstructured":"Rodriguez A, Reise SP, Haviland MG (2016) Evaluating bifactor models: calculating and interpreting statistical indices. Psychol Methods 21(2):137\u2013150","journal-title":"Psychol Methods"},{"issue":"1","key":"996_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.32614\/RJ-2019-040","volume":"11","author":"PJ Ferrando","year":"2019","unstructured":"Ferrando PJ, Lorenzo-Seva U, Navarro-Gonzalez D (2019) Unival: an FA-based R package for assessing essential unidimensionality using external validity Information. R J 11(1):401\u2013415","journal-title":"The R J"},{"key":"996_CR17","unstructured":"FACIT Fatigue Scale (Version 4). Updated 11\/16\/2007. Accessed 01\/08\/2024, http:\/\/www.ser.es\/wp-content\/uploads\/2015\/03\/FACIT-F_INDICE.pdf"},{"issue":"11","key":"996_CR18","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jval.2018.03.013","volume":"21","author":"I Montan","year":"2018","unstructured":"Montan I, L\u00f6we B, Cella D, Mehnert A, Hinz A (2018 Nov) General population norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale. Value Health 21(11):1313\u20131321. https:\/\/doi.org\/10.1016\/j.jval.2018.03.013","journal-title":"Value Health"},{"issue":"5","key":"996_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B et al. (1993) The European Organization for Research and treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365\u2013376","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"996_CR20","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/s0959-8049(01)00448-8","volume":"38 Suppl","author":"P Fayers","year":"2002","unstructured":"Fayers P, Bottomley A (2002 Mar) Quality of life research within the EORTC-the EORTC QLQ-C30. European organisation for Research and treatment of Cancer. Eur J Cancer 38 Suppl(4):S125\u201333. https:\/\/doi.org\/10.1016\/s0959-8049(01)00448-8","journal-title":"Eur J Cancer"},{"key":"996_CR21","unstructured":"EuroQol Research foundation. EQ-5D-5L User Guide. https:\/\/euroqol.org\/publications\/user-guides\/"},{"issue":"9","key":"996_CR22","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00277-022-04887-8","volume":"101","author":"D Cella","year":"2022","unstructured":"Cella D, Sarda SP, Hsieh R et al. (2022 Sep) Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study. Ann Hematol 101(9):1905\u20131914. https:\/\/doi.org\/10.1007\/s00277-022-04887-8","journal-title":"Ann Hematol"},{"key":"996_CR23","unstructured":"SAS\/STAT\u00ae 15.3 User\u2019s Guide. (2023) SAS Institute Inc"},{"key":"996_CR24","unstructured":"Hinkle DE, Jurs SG, Wiersma W (2003) Applied statistics for the behavioral sciences, 2nd edn. Houghton Mifflin"},{"issue":"2","key":"996_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability Research. J Chiropr Med 15(2):155\u2013163","journal-title":"J Chiropr Med"},{"issue":"1","key":"996_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1037\/1082-989X.1.1.30","volume":"1","author":"KO McGraw","year":"1996","unstructured":"McGraw KO, Wong SP (1996) Forming inferences about some intraclass correlation coefficients. Psychological Methods 1(1):30\u201346","journal-title":"Psychological Methods"},{"issue":"1","key":"996_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41687-021-00294-1","volume":"5","author":"D Eek","year":"2021","unstructured":"Eek D, Ivanescu C, Corredoira L, Meyers O, Cella D (2021 Mar 11) Content validity and psychometric evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue scale in patients with chronic lymphocytic leukemia. J Patient Rep Outcomes 5(1):27. https:\/\/doi.org\/10.1186\/s41687-021-00294-1","journal-title":"J Patient Rep Outcomes"},{"issue":"9","key":"996_CR28","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00520-010-0971-1","volume":"19","author":"D Cella","year":"2011","unstructured":"Cella D, Lai JS, Stone A (2011 Sep) Self-reported fatigue: one dimension or more? Lessons from the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire. Supportive Care In Cancer: Off J Multinational Assoc of Supportive Care in Cancer 19(9):1441\u20131450. https:\/\/doi.org\/10.1007\/s00520-010-0971-1","journal-title":"Supportive Care In Cancer: Off J Multinational Assoc Of Supportive Care In Cancer"},{"issue":"5","key":"996_CR29","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","volume":"27","author":"CAC Prinsen","year":"2018","unstructured":"Prinsen CAC, Mokkink LB, Bouter LM et al. (2018 May) COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res 27(5):1147\u20131157. https:\/\/doi.org\/10.1007\/s11136-018-1798-3","journal-title":"Qual Life Res"},{"issue":"11","key":"996_CR30","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/S0277-9536(99)00045-3","volume":"48","author":"MA Sprangers","year":"1999","unstructured":"Sprangers MA, Schwartz CE (1999 Jun) Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med 48(11):1507\u20131515","journal-title":"Soc Sci Med"},{"issue":"3","key":"996_CR31","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s11136-004-0830-y","volume":"14","author":"FJ Oort","year":"2005","unstructured":"Oort FJ (2005 Apr) Using structural equation modeling to detect response shifts and true change. Qual Life Res 14(3):587\u2013598. https:\/\/doi.org\/10.1007\/s11136-004-0830-y","journal-title":"Qual Life Res"},{"issue":"1","key":"996_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/2168479015622667","volume":"50","author":"CD Coon","year":"2016","unstructured":"Coon CD, Cappelleri JC (2016) Interpreting change in scores on patient-reported outcome Instruments. Ther Innov & Regul Sci 50(1):22\u201329","journal-title":"Ther Innov & Regul Sci"},{"key":"996_CR33","doi-asserted-by":"crossref","unstructured":"MacCallum RC, Browne MW, Sugawara HM (1996) Power analysis and determination of sample size for covariance structure modeling. Psychological Methods. 1 ed. 130\u2013149","DOI":"10.1037\/1082-989X.1.2.130"},{"issue":"3","key":"996_CR34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/BF02294365","volume":"52","author":"B Muth\u00e9n","year":"1987","unstructured":"Muth\u00e9n B, Kaplan D, Hollis M (1987) On structural equation modeling with data that are not missing completely at random. Psychometrika 52(3):431\u2013462","journal-title":"Psychometrika"},{"issue":"2","key":"996_CR35","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/0013164400602002","volume":"60","author":"B Thompson","year":"2000","unstructured":"Thompson B, Vacha-Haase T (2000) Psychometrics is Datametrics: the Test is not reliable. Educ and Psychological Meas 60(2):174\u2013195","journal-title":"Educ And Psychological Meas"},{"issue":"3","key":"996_CR36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/BF02310555","volume":"16","author":"LJ Cronbach","year":"1951","unstructured":"Cronbach LJ (1951) Coefficient alpha and the internal structure of Tests. Psychometrika 16(3):297\u2013334","journal-title":"Psychometrika"},{"key":"996_CR37","volume-title":"Test theory: a unified approach","author":"RP McDonald","year":"1999","unstructured":"McDonald RP (1999) Test theory: a unified approach. Lawrence Erlbaum Associates"},{"issue":"7080","key":"996_CR38","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1136\/bmj.314.7080.572","volume":"314","author":"JM Bland","year":"1997","unstructured":"Bland JM, Altman DG (1997) Cronbach\u2019s alpha. BMJ 314(7080):572","journal-title":"BMJ"},{"key":"996_CR39","unstructured":"Nunnally J, Bernstein I (1994) Psychometric theory, 3 edn. McGraw-Hill"},{"issue":"Supplement 1","key":"996_CR40","doi-asserted-by":"publisher","first-page":"7339","DOI":"10.1182\/blood-2023-186840","volume":"142","author":"C De Castro","year":"2023","unstructured":"De Castro C, Scheinberg P, Han B et al. (2023) Patient experience interviews with a novel treatment iptacopan for paroxysmal nocturnal hemoglobinuria. Blood 142(Supplement 1):7339\u20137339. https:\/\/doi.org\/10.1182\/blood-2023-186840","journal-title":"Blood"},{"issue":"Supplement 1","key":"996_CR41","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1182\/blood-2021-153127","volume":"138","author":"D Cella","year":"2021","unstructured":"Cella D, Johansson P, Ueda Y et al. (2021) Clinically important difference for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data. Blood 138(Supplement 1):1952\u20131952. https:\/\/doi.org\/10.1182\/blood-2021-153127","journal-title":"Blood"},{"issue":"Supplement 1","key":"996_CR42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1182\/blood-2023-179035","volume":"142","author":"AM Risitano","year":"2023","unstructured":"Risitano AM, de Castro CM, Han B et al. (2023) Patient-reported Improvements in Fatigue and Health-related quality of life in the Phase 3 studies apply-PNH and Appoint-PNH evaluating the use of iptacopan in C5 inhibitor-treated and treatment-na\u00efve patients with paroxysmal nocturnal hemoglobinuria. Blood 142(Supplement 1):487\u2013487. https:\/\/doi.org\/10.1182\/blood-2023-179035","journal-title":"Blood"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-026-00996-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-00996-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-00996-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:05:49Z","timestamp":1781629549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-026-00996-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["996"],"URL":"https:\/\/doi.org\/10.1186\/s41687-026-00996-4","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All interview documents were submitted to and approved by the relevant ethics authority in each country. All interview procedures were performed in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JM, SL, EA, NG, and GD are employees of Adelphi Values, which was compensated by Novartis for the conduct of the research reported here and the drafting of this manuscript. At the time of the research reported here, GN was an employee of Adelphi Values. DC is President of FACIT.org and has been a paid consultant to Novartis, unrelated to this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}